{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:04Z","timestamp":1793050924469,"version":"4.5.0"},"reference-count":34,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Liver Journal"],"published-print":{"date-parts":[[2023,10,30]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Pegylated interferon (Peg-IFN) is recommended as first-line therapy for chronic hepatitis B (CHB) but has significant side effects and is rarely used compared to oral nucleos(t)ide analogues (NA). There are limited recent clinical efficacy or economic analysis data comparing approved CHB therapy in North America. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> This retrospective study examined clinical outcomes, off-treatment durability, and cost-effectiveness of Peg-IFN versus NA for CHB. Demographic (age, sex, ethnicity), clinical data (i.e., liver tests, hepatitis B virus DNA, serology, transient elastography) and documented side effects were collected by retrospective chart review of patients followed in the University of Calgary Liver Unit who received Peg-IFN therapy from January 2007 to December 2020. The cost-effectiveness of Peg-IFN versus NA therapy was modelled over a 10-year time horizon. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Sixty-eight CHB patients were treated with Peg-IFN (median age 45.65, 74% male, 84% Asian); 50\/68 (74%) completed 48 weeks of treatment with a median follow-up of 6.54 years (interquartile range 5.07). At the last known follow-up, 23\/68 (34%) have not required NA treatment and one had HBsAg loss; 27 have been started on NA. Predictors of obtaining a sustained virological response included being hepatitis B e antigen-negative at treatment end and a quantitative hepatitis B surface antigen &lt;1000 IU\/mL. Economic modelling showed that finite Peg-IFN was not cost-effective versus NA at a 10-year time horizon. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> PEG-IFN remains a potential treatment for CHB although there is a significant intolerance\/failure rate. Using PEG-IFN based on patient preference is reasonable and optimal patient selection may improve treatment cost-effectiveness. <\/jats:p><\/jats:sec>","DOI":"10.3138\/canlivj-2022-0043","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T20:45:26Z","timestamp":1674074726000},"page":"305-313","source":"Crossref","is-referenced-by-count":4,"title":["A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B"],"prefix":"10.3138","volume":"6","author":[{"given":"Stephen E","family":"Congly","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"O\u2019Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Syed","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haylock-Jacobs","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Israelson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Pinto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S","family":"Coffin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"issue":"4","key":"r1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12072-018-9884-8","volume":"12","author":"Ginzberg D","year":"2018","journal-title":"Hepatol Int"},{"issue":"10003","key":"r2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"Schweitzer A","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"r3","doi-asserted-by":"crossref","first-page":"e0196452","DOI":"10.1371\/journal.pone.0196452","volume":"13","author":"Park H","year":"2018","journal-title":"PLoS ONE"},{"key":"r4","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1177\/1010539514560057","volume":"27","author":"Zhang H","year":"2015","journal-title":"Asia Pac J Public Health"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2018-0008"},{"issue":"1","key":"r6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"Sarin SK","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"r7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"Terrault NA","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"r8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"r9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","volume":"14","author":"Brouwer WP","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"r10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"Marcellin P","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"r11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","volume":"23","author":"Lopatin U","year":"2019","journal-title":"Clin Liver Dis"},{"key":"r12","author":"Hepatitis B Foundation","journal-title":"Drug watch compounds in development for chronic hepatitis B"},{"issue":"1","key":"r13","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.9778\/cmajo.20180108","volume":"7","author":"Congly SE","year":"2019","journal-title":"CMAJ Open"},{"issue":"6","key":"r14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"Shaheen AA","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"r15","unstructured":"Government of Alberta. Alberta drug benefit list effective April 1, 2021; 2021. https:\/\/www.ab.bluecross.ca\/dbl\/pdfs\/dbl_full_list.pdf (Accessed July 11, 2022)."},{"key":"r16","volume-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"Canadian Agency for Drugs and Technology in Health","year":"2017","edition":"4"},{"issue":"4","key":"r17","first-page":"453","volume":"5","author":"Azhari H","year":"2022","journal-title":"CanLivJ"},{"issue":"9","key":"r18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1155\/2010\/931326","volume":"24","author":"Marotta P","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"r19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cgh.2014.06.022","volume":"13","author":"Lo AO-S","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"r20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5604\/01.3001.0009.8590","volume":"16","author":"Oyag\u00fcez I","year":"2017","journal-title":"Ann Hepatol"},{"issue":"4","key":"r21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3851\/IMP2555","volume":"18","author":"Iannazzo S","year":"2013","journal-title":"Antivir Ther"},{"issue":"6","key":"r22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jval.2015.05.007","volume":"18","author":"Bermingham SL","year":"2015","journal-title":"Value Health"},{"issue":"1","key":"r23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/liv.15027","volume":"42","author":"Toy M","year":"2022","journal-title":"Liver Int"},{"issue":"26","key":"r24","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"Lau GKK","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"r25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"Marcellin P","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"r26","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","volume":"63","author":"Ahn SH","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"1","key":"r27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.25636","volume":"56","author":"Sonneveld MJ","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"r28","first-page":"712","volume":"31","author":"Lampertico P","year":"2018","journal-title":"Ann Gastroenterol"},{"issue":"6","key":"r29","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"Buster EHCJ","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"r30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bpg.2008.11.007","volume":"22","author":"Buster EHCJ","year":"2008","journal-title":"Best Practice Res Clin Gastroenterol"},{"issue":"4","key":"r31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","volume":"8","author":"Sulkowski MS","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"r32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.12755","volume":"24","author":"Li S-Y","year":"2017","journal-title":"J Viral Hepat"},{"issue":"10","key":"r33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14712598.2018.1518423","volume":"18","author":"Ren P","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"r34","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","volume":"19","author":"Choi HSJ","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Canadian Liver Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/canlivj.utpjournals.press\/doi\/pdf\/10.3138\/canlivj-2022-0043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:13:52Z","timestamp":1703157232000},"score":1,"resource":{"primary":{"URL":"https:\/\/canlivj.utpjournals.press\/doi\/10.3138\/canlivj-2022-0043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,10,30]]}},"alternative-id":["10.3138\/canlivj-2022-0043"],"URL":"https:\/\/doi.org\/10.3138\/canlivj-2022-0043","relation":{},"ISSN":["2561-4444"],"issn-type":[{"value":"2561-4444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}